Disc Medicine (IRON) is the lead sponsor of 7 active clinical trials listed on ClinicalTrials.gov[4], including 2 Phase 3[1], 4 Phase 2[2], 3 Phase 1[3].
Trial NCT05883748[5] evaluates DISC-1459 in Erythropoietic Protoporphyria with a target enrollment of 230 participants. Trial NCT06910358[6] evaluates Placebo in Erythropoietic Protoporphyria (EPP) with a target enrollment of 150 participants.
No Form 4 insider filings for IRON were recorded at the SEC in the past 30 days[7].